Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
JPMA Sacks Hasegawa as Vice President after Business Improvement Order
The Japan Pharmaceutical Manufacturers Association (JPMA) has dismissed Takeda Pharmaceutical Chairman Yasuchika Hasegawa as its vice president after the company faced a business improvement order for running improper advertisements. At a press conference following its board meeting on July 2,…
To read the full story
Related Article
- JPMA Extends Suspension of Activities for Takeda as It Awaits Ruling of Administrative Authority on Blopress Scandal
May 29, 2015
- JPMA Suspends Hasegawa’s Veep Duties for Another 2 Months over CASE-J
March 20, 2015
- R&D Tax Credit Revamp (2): No Deadline Set, yet Revision Could Come Up for Debate towards FY2017
January 21, 2015
- R&D Tax Credit Revamp (1): New Scheme for Open Innovation Research Significant in 3 Ways
January 20, 2015
- Japan Govt OKs FY2015 Tax Reform Plan
January 15, 2015
- JPMA to Suspend Hasegawa’s Veep Activities for Another 6 Months over CASE-J
September 19, 2014
- Dainippon Pres. Tada Elected New Chief of JPMA
May 22, 2014
- JPMA Suspends Veep Hasegawa’s Duties for 6 Months over CASE-J
April 4, 2014
ORGANIZATION
- Biotech Group Calls for Post-IPO Startups to Get AMED Support
August 19, 2026
- EFPIA Executive Hails Japan’s Honebuto as “Blueprint” for Europe
August 17, 2026
- New Chuikyo Pharmacist Rep Urges 2027 Revision to Stay within 4-Minister Deal
August 3, 2026
- Ectopic Fat Research Group Launches to Push Cross-Disciplinary Studies
July 31, 2026
- JPMA Chief Seeks Concrete Reforms to Reward Innovation after Honebuto
July 31, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…